Y Intercept (Hong Kong) LTD Bei Gene, Ltd. Transaction History

Y Intercept (Hong Kong) LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$141.8 - $181.47 $751,398 - $961,609	5,299 New	5,299 $828,000
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $645,193 - $807,541	3,587 New	3,587 $645,000
Q2 2022 Aug 08, 2022	SELL	$121.11 - $216.05 $278,431 - $496,698	-2,299 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $336,849 - $619,718	2,299 New	2,299 $434,000
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $234,624 - $378,951	-940 Closed	0 $0
Q2 2021 Aug 26, 2021	BUY	$292.75 - $367.01 $275,185 - $344,989	940 New	940 $323,000
Q2 2021 Aug 12, 2021	SELL	$292.75 - $367.01 $180,334 - $226,078	-616 Closed	0 $323,000
Q1 2021 May 12, 2021	BUY	$260.64 - $382.12 $160,554 - $235,385	616 New	616 $205,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.